
|Articles|February 1, 2002
LHRH investigation still active, despite settlement
San Francisco-Despite a settlement by TAP Pharmaceuticals last fall on charges concerning fraudulent pricing and marketing of leuprolide acetate (Lupron)
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5








